Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma

Table 2 Systematic review and meta-analyses investigating hepatocellular carcinoma risk reduction in patients receiving nucleos(t)ide analogues vs untreated controls

Ref.	No. of studies	No. of patients (T/C)	OR (95%CI)	P
Papatheodoridis et al[51]	3	1313 (779/534)	0.43 (0.25-0.74)	0.002
Zhang et al[52]	6	3644 (2035/1609)	0.26 (0.15-0.47)	< 0.00001
Singal et al[53]	6	6877 (3306/3571)	0.48 (0.38-0.61)	< 0.00001
Sung et al[54]	5	2289 (1267/1022)	0.22 (0.10-0.50)	0.0003

T: Treatment group; C: Control group.